SynthesisFrontiers in oncology2025
Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Associations between systemic immune-inflammation index and immune-related hypothyroidism in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective study.Frontiers in oncology · 2026Article
- Predictive value of pre-existing thyroid autoantibodies for PD-1 inhibitor-induced hypothyroidism: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- The dual nature of immunotherapy in female reproductive disorders: immune homeostasis and clinical challenges.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To systematically evaluate the incidence of thyroid adverse events in patients with baseline positive thyroid antibodies following treatment with immune checkpoint inhibitors (ICIs). Methods: In this systematic review and meta-analysis, we utilized PubMed, Embase, and Cochrane Library databases to identify studies that detail the thyroid immune-related adverse events (irAEs) among cancer patients undergoing treatment with ICIs. Literature was screened according to inclusion and exclusion criteria, and data were extracted. Meta-analysis was conducted using RevMan 5.4 and Stata 16.0 software, with adherence to PRISMA 2020 guidelines. Results: A total of 13 studies involving 2,059 patients treated with ICIs for malignancies were included, with 594 cases of thyroid irAEs reported post-treatment. Meta-analysis revealed that the incidence of thyroid irAEs in patients with baseline positive thyroid antibodies was 66.7% (95% CI: 45.1%, 85.5%; Z=7.825, Conclusion: Patients with baseline positive thyroid antibodies experience a higher incidence of thyroid irAEs following ICI treatment. In comparison to TPOAb, baseline TgAb positivity showed a non-significant trend toward higher thyroid irAE risk (based on limited studies), but further evidence is needed to confirm this relationship. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42025635209.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.